Terrance Cole's Choice: Reformer or Cover-Up Artist? New DEA Administrator Terrance Cole stands at a crossroads:
Break rank, clean house, and restore the DEA's marijuana research credibility by approving MMJ BioPharma's application.
Or protect the old guard's corruption-and go down as the next puppet in a failed prohibitionist machine.
Quotes From Inside the Agency Reveal Systemic Corruption, Regulatory Negligence, and Public Health Betrayal.
The DEA's war on cannabis research is not just a failure of policy-it's a failure of morality.
Read More-Debuting a "coming soon" campaign for tubeless Pivot patch pump
- Expects special 510(k) filing for Pivot product in October
- Will introduce first level of its gamified training application developed by Level Ex, developers of the Level One diabetes-management game
Read More
Advanced AI Solutions Provide Measurable Short-Term ROI, Strategic Decision-Making Benefits and Operational Improvements; New Survey Highlights Leading AI Healthcare Vendors Based on Client Satisfaction and Outcomes
Read MoreNew data from Eurofins Discovery show that Telomir-1 blocks enzymes that drive disease by turning off critical genes-highlighting its potential to treat cancer, autoimmune conditions, neurodegeneration, and metabolic disorders through epigenetic modulation.
Read More
Where Is the DEA? The Real Threat Isn't Research-It's Rotten Weed.
"This is the height of hypocrisy," said Duane Boise, CEO MMJ. "DEA bureaucrats are blocking clean cannabis grown in a DEA inspected cultivation facility, while contaminated products circulate freely under their watch. The agency has abandoned its duty to protect patients."
Read More
NDA for icotrokinra for the treatment of adults and adolescents 12 years of age and older with moderate to severe plaque psoriasis (PsO) submitted to U.S. FDA in July
ANTHEM Phase 2b trial data of icotrokinra in ulcerative colitis scheduled for an oral presentation at the 33rd United European Gastroenterology Week (UEGW) on October 7th
Phase 3 VERIFY trial data set of rusfertide in polycythemia vera (PV) presented during plenary session at ASCO; U.S. NDA filing on track for Q4
Cash, cash equivalents and marketable securities of $673.0 million as of June 30, 2025, anticipated to provide cash runway through at least end of 2028
Read More
Electromedical Technologies (OTC: EMED) outlines key financial restructuring milestones, upcoming product updates, and new strategic partnerships to drive sustainable growth in the pain management market.
Read MorePeer-reviewed research demonstrates dramatic improvement in identifying and closing quality gaps for Medicaid patients, outperforming current methods by 35 percentage points
Read More
CID-103 is a potential best-in-class, anti-CD38 monoclonal antibody; binds to unique CD38 epitope
Phase 1 study in adults with active and chronic active renal allograft AMR planned to initiate
AMR is a leading cause of kidney transplant loss, leading to dialysis and/or repeat renal transplant
-Company closes approximately $5.47 million in equity financing in 2Q/3Q25
-TH104 potentially fills a critical National Security Need against Weaponized Fentanyl
-TH023 may fulfill the promise of delivering a safe and effective oral antibody medication against inflammation
-Company Strengthens Operational Leadership, Corporate Governance and Accounting
From Dr. Lyle Craker, University of Mass. to Duane Boise, CEO of MMJ BioPharma Cultivation;
Dr. Craker died still waiting for the DEA to embrace cannabis science. The same cannot be allowed to happen to MMJ BioPharma Cultivation, whose FDA Multiple Sclerosis and Huntington's Disease clinical trials could bring relief to patients suffering from incurable neurological disorders.
Read More
With the confirmation of incoming DEA Administrator Terrance Cole, the opportunity for reform has arrived. The DEA must choose between outdated drug war politics and advancing public health.
MMJ International Holdings Issues Clarification on Irvine Labs.
Read MoreReports second quarter revenues of $0.1 billion, GAAP net loss of $(0.8) billion and GAAP EPS of $(2.13)
Updates 2025 projected revenue range to $1.5 to $2.2 billion, reflecting a $300 million reduction at the high end, primarily driven by timing of deliveries for contracted revenue into the first quarter of 2026
Improves 2025 expected GAAP operating expenses by approximately $400 million to a range of $5.9 to $6.1 billion
Reiterates 2025 expected year-end cash balance of approximately $6 billion
Announced three recent U.S. FDA approvals and positive Phase 3 efficacy results for seasonal influenza vaccine
Read More
Newly confirmed DEA Administrator Terrance Cole faces a defining choice: Will he break ranks with the agency's deeply entrenched anti-cannabis cabal-or will he become just another DEA figurehead parroting the same tired "gateway drug" propaganda while Americans suffer, science stalls, and corruption thrives?
The public, the scientific community, and thousands of patients are watching-and the window for Cole to make a meaningful impact is rapidly closing.
Read More
Professional & Friendly:
Now accepting new patients with short wait times and personalized care near Maple Shade and Riverton
Community-Oriented:
Local dental office steps up to serve patients after recent practice closures in the area
Value-Focused:
Gentle, affordable, and timely dental care available just minutes from Maple Shade and Riverton
Read More
